The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.50
Bid: 29.00
Ask: 30.00
Change: -0.50 (-1.67%)
Spread: 1.00 (3.448%)
Open: 29.50
High: 29.50
Low: 29.50
Prev. Close: 30.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update & Notice of Results

11 Nov 2020 07:00

RNS Number : 9031E
Ilika plc
11 November 2020
 

Ilika plc

("Ilika" or the "Company")

 

Trading Update

& Notice of Half-year Results

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology, is today providing an update on trading for the six months ended 31 October 2020.

 

Financial Highlights

 

Trading in the first half of the year has been broadly in-line with our expectations in accordance with our assessment of the financial impact of COVID-19 restrictions, which resulted in the three-month shutdown of the Stereax pilot line between March and June 2020. Despite the restrictions, revenue recognition for the period was £1.3m (H1 2019: £1.5m). The EBITDA loss for the period remained unchanged relative to the EBITDA loss for the same period last year at £1.0m (H1 2019: loss of £1.0m). Cash and cash equivalents at the period end were £12.4m (H1 2019: £1.9m).

 

Operating Highlights

 

StereaxÒ

Following the successful conclusion of our over-subscribed £15m equity placing in April 2020, the Company is now implementing the manufacturing scale-up plans for StereaxÒ, Ilika's miniature solid-state batteries designed for industrial wireless sensors in hostile environments and medical implants. This involves selecting a fabrication facility (FAB) into which the Company will install key equipment for its proprietary cell manufacturing process. The Company is well advanced with that selection process and still expects to finalise details by the end of 2020 with key tools, which have already been ordered, expected to be installed in the first half of FY22 and manufacturing commencing by the second half of FY22. This will result in a 70x increase in Stereax production capacity by the end of 2021. In order to manage this process the Company has made a key hire, Paul Marron, Technology Transfer Director.

 

Goliath Programme

The Company's continued collaborations with its Faraday Battery Challenge partners have resulted in a steady increase in the Goliath large format cell performance. The plans for the scale-up of the Goliath programme progressed in September 2020 with the announcement of the framework agreement with the UK Battery Industrialisation Centre, or UKBIC. Ilika's Goliath pre-pilot line in Romsey is a prototyping facility with a capacity of 1 kWh/week, which we intend to increase to 10 kWh/week by 2022 with the support of further grant funding. Beyond that, the UKBIC will facilitate the production of 5MWh/week, enabling the launch of the first Goliath-powered commercial products.

 

Notice of Results

 

Ilika expects to announce half-year results for the six months ended 31 October 2020 on Thursday 14 January 2021.

 

Analyst Briefing

The management team will be hosting a remote analyst briefing on the day, 14 January 2021, at 9.30am. Analysts who wish to attend should contact Lianne Cawthorne at Walbrook PR on +44(0)20 7933 8780 or email ilika@walbrookpr.com to register. 

 

Investor Presentation

An investor presentation will be held on the day, 14 January 2021, at 4.30pm and will be hosted through the digital platform, Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Ilika plc via the following link: https://www.investormeetcompany.com/ilika-plc/register-investor

 or for more information please contact Walbrook PR at ilika@walbrookpr.com. 

 

Ilika's CEO Graeme Purdy, stated, "Despite the operational challenges posed by the restrictions accompanying the COVID-19 pandemic, Ilika has progressed both the implementation of its manufacturing plans for Stereax and continued the development of its Goliath large format cells. The Company has a clear pathway to increased production, revenue generation and cash flow break even, with a focus on a number of exciting target markets. We look forward to maintaining the on-schedule implementation of our plans in the second half of our current financial year and updating the market on our progress."

 

For more information contact:

 

Ilika plc

 

 

www.ilika.com

Graeme Purdy, Chief Executive

Via Walbrook PR

Steve Boydell, Finance Director

 

 

 

Liberum Capital Limited

Tel: 020 3100 2000

Andrew Godber, Cameron Duncan, William Hall, Nikhil Varghese

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / Ilika@walbrookpr.com

Tom Cooper

Mob: 0797 122 1972

Lianne Cawthorne

Mob: 07584 391 303

Nick Rome

Mob: 07748 325 236

 

Notes to editor and corporate video:

Please click link here to view latest corporate video and overview:

https://www.ilika.com/latest-news/ilika-investor-update-november-2020

Ilika plc (LON: IKA) is a pioneer in solid-state battery technology with their innovative Stereax micro batteries designed for Industrial IoT and MedTech markets, and their Goliath large format batteries for the electric vehicle and consumer electronics markets. Stereax battery technology offers compelling advantages over conventional lithium ion batteries, including smaller footprint, high energy density, non-toxic materials, faster charging, increased cycle life, low leakage and reduced flammability. Stereax solid-state batteries are also customisable in shape and form, stackable and operational at high temperatures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFSFUSESSEIF
Date   Source Headline
23rd Aug 20131:25 pmRNSPosting of Annual Report & Notice of AGM
2nd Aug 20135:02 pmRNSConversion of Securities
30th Jul 20137:00 amRNSContract Renewals and Grant Award
19th Jul 20132:50 pmRNSHolding(s) in Company
19th Jul 201311:17 amRNSHolding(s) in Company
18th Jul 20137:00 amRNS£3.3 million EPSRC Grant Award to Southampton Univ
15th Jul 20137:00 amRNSFinal Results
21st May 20131:09 pmRNSHolding(s) in Company
20th May 20137:00 amRNSDirectorate Change and Conversion of Securities
17th May 20133:57 pmRNSPlacing - Replacement
17th May 20137:00 amRNSPlacing
1st May 20137:00 amRNSFuel Cell Catalyst Patent Granted in Japan
22nd Apr 20137:00 amRNSContract with new European Customer
16th Apr 20137:00 amRNSTrading Update
21st Feb 20137:00 amRNSRenewal of Contract
29th Jan 20137:00 amRNSCompletion of Laboratory Facility Expansion
18th Jan 20133:28 pmRNSHolding(s) in Company
17th Jan 20135:46 pmRNSHolding(s) in Company
17th Jan 201311:16 amRNSHolding(s) in Company
15th Jan 20135:21 pmRNSHolding(s) in Company
10th Jan 20137:00 amRNSInterim Results
21st Dec 20127:00 amRNSGrant of Fuel Cell Catalyst Patent
18th Dec 20121:41 pmRNSCompletion of Disposal
17th Dec 20127:00 amRNSConversion of Securities
11th Dec 20127:00 amRNSRenewal of Contract
29th Nov 20124:44 pmRNSHolding(s) in Company
28th Nov 20125:00 pmRNSHolding(s) in Company
27th Nov 20122:18 pmRNSHolding(s) in Company
19th Nov 20127:00 amRNSEnergizer Relationship Update
22nd Oct 20127:00 amRNSTrading Update
5th Oct 20127:00 amRNSHolding(s) in Company
5th Oct 20127:00 amRNSTotal Voting Rights
18th Sep 20127:00 amRNSDiscontinuing of wound care products and services
14th Sep 20127:00 amRNSCarbon Trust Investment
7th Sep 20121:27 pmRNSResult of AGM
7th Sep 20127:00 amRNSAGM Statement
9th Aug 20127:00 amRNSPosting of Annual Report & Notice of AGM
19th Jul 20127:00 amRNSFinal Results
14th Jun 20127:14 amRNSChange of Adviser
1st Jun 201210:01 amRNSTotal Voting Rights
18th May 20127:00 amRNSTrading Update
17th May 20127:00 amRNSConversion of Securities
2nd May 20127:00 amRNSVapour Deposition Method US Patent Grant
1st May 20123:00 pmRNSHolding(s) in Company
30th Apr 201210:27 amRNSDirector's Dealings
30th Apr 201210:22 amRNSTotal Voting Rights
25th Apr 20122:02 pmRNSHolding(s) in Company
23rd Apr 20122:44 pmRNSHolding(s) in Company
23rd Apr 20128:01 amRNSDirector/PDMR Shareholding
20th Apr 201212:49 pmRNSGeneral Meeting Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.